Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase

Journal of Stroke and Cerebrovascular Diseases

Volumn 23, Issue 10, 2014, Pages 2894-2899

  Tsuruoka, Atsushi ^a   Atsumi, Chihiro ^a   Mizukami, Heisuke ^a   Imai, Takeshi ^a   Hagiwara, Yuta ^a   Hasegawa, Yasuhiro ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hemorrhagic transformation; Matrix metalloproteinase 9; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; C REACTIVE PROTEIN; CHOLESTEROL; D DIMER; GELATINASE A; GELATINASE B; GLUCOSE; HEMOGLOBIN A1C; INTERLEUKIN 6; NORPHENAZONE; TRIACYLGLYCEROL; BIOLOGICAL MARKER; FIBRINOLYTIC AGENT; MMP9 PROTEIN, HUMAN; PHENAZONE; PHENYLMETHYLPYRAZOLONE; SCAVENGER; TISSUE PLASMINOGEN ACTIVATOR;

AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOT LYSIS; BODY MASS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ENZYME REPRESSION; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TIME; TRIACYLGLYCEROL BLOOD LEVEL; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; ENZYMOLOGY; FIBRINOLYTIC THERAPY; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; MIDDLE AGED; PREDICTIVE VALUE; RISK FACTOR; STATISTICAL MODEL; STROKE; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; ANTIPYRINE; AREA UNDER CURVE; BIOMARKERS; CEREBRAL HEMORRHAGE; FEMALE; FIBRINOLYTIC AGENTS; FREE RADICAL SCAVENGERS; HUMANS; JAPAN; LINEAR MODELS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84923228236     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2014.07.022     Document Type: Article

References (35)

1. Watanabe T, Morita I, Nishi H, et al. Preventive effect of MCI-186 on 15-HPETE-induced vascular endothelial cell injury in vitro. Prostaglandins Leukot Essent Fatty Acids 1988;33:81-87.
2. Yamamoto T, Yuki S,Watanabe T, et al. Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Res 1997;762:240-242.
3. Abe K, Yuki S, Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 1988;19:480-485.
4. Nishi H, Watanabe T, Sakurai H, et al. Effect of MCI-186 on brain edema in rats. Stroke 1989;20:1236-1240.
5. Yamashita T, Kamiya T, Deguchi K, et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab 2009;29:715-725.
6. Yagi K, Kitazato KT, Uno M, et al. Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke 2009;40:626-631.
7. Toyoda K, Fujii K, Kamouchi M, et al. Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci 2004;221:11-17.
8. Zhang N, Komine-Kobayashi M, Tanaka R, et al. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 2005;36:2220-2225.
9. Amemiya S, Kamiya T, Nito C, et al. Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. Eur J Pharmacol 2005;516:125-130.
10. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598-603.
11. Fernandez-Cadenas I, Del Rio-Espinola A, Carrera C, et al. Role of MMP9 gene in hemorrhagic transformations after tissue-type plasminogen activator treatment in stroke patients. Stroke 2012;43:1398-1400.
12. Isahaya K, Yamada K, Yamatoku M, et al. Effects of edaravone, a free radical scavenger, on serum levels of inflammatory biomarkers in acute brain infarction. J Stroke Cerebrovasc Dis 2012;21:102-107.
13. Murata Y, Rosell A, Scannevin RH, et al. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke 2008;39:3372-3377.
14. Fan X, Lo EH, Wang X. Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats. Stroke 2013; 44:745-752.
15. Wang CX, Ding X, Noor R, et al. Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats. J Cereb Blood Flow Metab 2009;29:1683-1694.
16. Liu R, Liu Q, He S, et al. Combination Therapy of 17b- Estradiol and Recombinant Tissue Plasminogen Activator for Experimental Ischemic Stroke. J Pharmacol Exp Ther 2010;332:1006-1012.
17. Mishiro K, Ishiguro M, Suzuki Y, et al. A broadaspectrum matrix metalloproteinase inhibitor prevents hemorrhagic complications induced by tissue plasminogen activator in mice. Neuroscience 2012;205:39-48.
18. Amaro S, Obach V, Cervera A, et al. Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke: a proof-ofconcept study. J Neurol 2009;256:651-656.
19. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
20. Hacke W, Kaste M, Fieschi C, et al. Randomised doubleblind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-1251.
21. Greenhouse SW, Geisser S. On methods in the analysis of profile data. Psychometrika 1959;24:95-112.
22. Kern R, Nagayama M, Toyoda K, et al. Comparison of the European and Japanese guidelines for the management of ischemic stroke. Cerebrovasc Dis 2013;35:399-401.
23. Amaro S, Soy D, Obach V, et al. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. Stroke 2007; 38:2173-2175.
24. Romanos E, Planas AM, Amaro S, et al. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 2007;27:14-20.
25. Amaro S, Canovas D, Castellanos M, et al. The URICOICTUS study, a phase 3 study of combined treatment with uric acid and rtPA administered intravenously in acute ischaemic stroke patients within the first 4.5 h of onset of symptoms. Int J Stroke 2010;5:325-328.
26. Ramos-Fernandez M, Bellolio MF, Stead LG. Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis 2011;20:47-54.
27. Castellanos M, Sobrino T, Millán M, et al. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke 2007;38:1855-1859.
28. Barr TL, Latour LL, Lee KY, et al. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke 2010; 41:e123-e128.
29. Inzitari D, Giusti B, Nencini P, et al. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death. Stroke 2013;44:2901-2903.
30. Shibata H, Araki S, Izawa M, et al. Phase I clinical study of MCI-186 (edaravone, 3-methyl-1-phenyl-2-pyrazolin- 5-one) in healthy volunteeres: safety and armacokinetics of single and multiple administrations. Japanese J Clin Pharmacol Ther 1998;29:863-876.
31. Lee SR, Kim HY, Rogowska J, et al. Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J Neurosci 2006; 26:3491-3495.
32. Wang L, Zhang ZG, Zhang RL, et al. Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J Neurosci 2006;26:5996-6003.
33. Zhao BQ, Tejima E, Lo EH. Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke 2007;38:748-752.
34. Sood RR, Taheri S, Candelario-Jalil E, et al. Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired longterm recovery after stroke in rat brain. J Cereb Blood Flow Metab 2007;28:431-438.
35. Kaste M, Murayama S, Ford GA, et al. Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. Cerebrovasc Dis 2013;36:196-204.